Newly released book edited by Matt Reaney, (PhD, CPsychol, CSci, MSc), head, science and analytics, PCS, at IQVIA focuses on patient experience data with all levels of clinical research in mind.
IQVIA’s Patient Centered Solutions (PCS) team is distributing print copies of a newly released book, Using Patient Experience Data to Evaluate Medical Interventions. Generating, Understanding and Using Patient Experience Data Within and Alongside Clinical Trials, at the DIA meeting in Boston at the end of this month. If you are not on hand to pick up a complimentary copy, it will also be available for purchase at the Kindle store as an eBook.
Edited by Matt Reaney, (PhD, CPsychol, CSci, MSc), head, science and analytics, PCS, at IQVIA, the content is timely and the company believes it has the potential to become the authoritative text on patient-experience data (PED) in drug development. It was created with all levels and roles of clinical research in mind, with the intent to use the content to facilitate their work in bringing their products to the market.
Reaney outlines in Chapter 1, “Patient experience data (PED) in intervention development – what it is, why you should care, and how this book can help?” He writes, “The relevance of PED extends beyond patientlevel healthcare and into the development of new interventions. Indeed, understanding PED in intervention development is an important precursor to patient-focused healthcare provision. The goal of intervention development has long been to maximize health and well-being, but it is only recently that developers and sponsors of intervention development have recognized the importance of the patient experience in achieving this goal.”
The book is broken down into four important sections of PED—generating, understanding, using, and developing a PED strategy. IQVIA contributing authors range the professional functions within the organization from PCS, to statistics, research, endpoints, and many more to reflect their expertise to the included sections.
Lisa Henderson, editor-in-chief, Applied Clinical Trials